Cognitive behaviour therapy for improving social recovery in psychosis: Cost-effectiveness analysis

Schizophrenia Research

Volumn 112, Issue 1-3, 2009, Pages 158-163

  Barton, Garry R ^a   Hodgekins, Jo ^a   Mugford, Miranda ^a   Jones, Peter B ^b,c   Croudace, Tim ^b   Fowler, David ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CBT; Cost effectiveness; Psychosis

Indexed keywords

ADULT; ARTICLE; CASE MANAGEMENT; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SOCIAL CARE; THERAPY EFFECT;

ADOLESCENT; ADULT; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349127517     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.03.041     Document Type: Article

References (40)

1. Appleby L. Mental Health Ten Years On: Progress on Mental Health Care Reform (2007). http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_074235.pdf Available at http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_074235.pdf (accessed on April 16th 2008)
2. Barton G.R., Briggs A.H., and Fenwick E.A. Optimal cost-effective decisions: the role of the cost-effectiveness acceptability curve (CEAC), cost-effectiveness acceptability frontier (CEAF) and expected value of perfect information (EVPI). Value Health 11 (2008) 886-897
3. Barton G.R., Stacey P.C., Fortnum H.M., and Summerfield Q. Hearing-impaired children in the UK, II: cost of compulsory education and cochlear implantation. Ear Hear. 27 (2006) 187-207
4. Beck A.T., Steer R.A., and Brown G.K. BDI-II Manual (1996), The Psychological Corporation, San Antonio, TX
5. Beecham J., and Knapp M. Costing psychiatric interventions. In: Thornicroft G., Brewin C.R., and Wing J. (Eds). Measuring Mental Health Needs (1992), Gaskell, London
6. Beecham J., Sleed M., Knapp M., Chiesa M., and Drahorad C. The costs and effectiveness of two psychosocial treatment programmes for personality disorder: a controlled study. Eur. Psychiatry 21 (2006) 102-109
7. Briggs A.H., Sculpher M.J., and Claxton K. Decision Modelling for Health Economic Evaluation (2006), Oxford University Press, New York
8. Brooks R. EuroQol: the current state of play. Health Policy 37 (1996) 53-72
9. Butler G. Overcoming Social Anxiety: A Self-help Guide Using Cognitive-behavioural Techniques (1999), Constable & Robinson Ltd, London
10. Byford S., Knapp M., Greenshields J., Ukoumunne O.C., Jones V., Thompson S., Tyrer P., Schmidt U., Davidson K., and (POMACT Group). Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychol. Med. 33 (2003) 977-986
11. Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ. 8 (1999) 269-274
12. Curtis L. Unit costs of health and social care (2007), Personal Social Services Research Unit, The University of Kent
13. Dakin H.A., Devlin N.J., and Odeyemi I.A. Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making. Health Policy 77 (2006) 352-367
14. Davies L.M., Barnes T.R.E., Jones P.B., Lewis S., Gaughran F., Hayhurst K., Markwick A., Lloyd H., and on behalf of the CUTLASS Team. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health 11 (2008) 549-562
15. Dixon L., Hoch J.S., Clark R., Bebout R., Drake R., McHugo G., and Becker D. Cost-effectiveness of two vocational rehabilitation programs for persons with severe mental illness. Psychiatr. Serv. 53 (2002) 1118-1124
16. Dolan P. Modelling valuations for EuroQol health states. Med. Care 35 (1997) 1095-1108
17. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., and Stoddart G.L. Methods for the Economic Evaluation of Health Care Programmes. (3rd Edition) (2005), Oxford University Press, New York
18. Fayers P., and Machin D. Quality of Life: Assessment, Analysis and Interpretation (2000), Wiley, Chichester
19. Fenton W.S., Hoch J.S., Herrell J.M., Mosher L., and Dixon L. Cost and cost-effectiveness of hospital vs residential crisis care for patients who have serious mental illness. Arch. Gen. Psychiatry 59 (2002) 357-364
20. Fenwick E., Claxton K., and Sculpher M.J. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 10 (2001) 779-787
21. Fowler, D., Hodgekins, J., Painter, M., Reilly, T., Crane, C., Macmillan, I., Mugford, M., Croudace, T., Jones, P.B., in press. Cognitive behaviour therapy for improving social recovery in psychosis: a randomised controlled trial (Improving Social Recovery in Psychosis). Psychol Med. doi:10.1017/S0033291709005467.
22. Glick H.A., Doshi J.A., Sonnad S.S., and Polsky D. Economic Evaluation in Clinical Trials (2007), Oxford University Press, Oxford
23. Harrison G., Croudace T., Mason P., Glazebrook C., and Medley I. Predicting the long-term outcome of schizophrenia. Psychol. Med. 26 (1996) 697-705
24. Hawthorne G., and Elliott P. Imputing cross-sectional missing data: comparison of common techniques. Aust. N. Z. J. Psychiatry 39 (2005) 583-590
25. Hiller W., Fichter M.M., and Rief W. A controlled treatment study of somatoform disorders including analysis of healthcare utilization and cost-effectiveness. J. Psychosom. Res. 54 (2003) 369-380
26. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
27. Kennedy T.M., Chalder T., McCrone P., Darnley S., Knapp M., Jones R.H., and Wessely S. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technol. Assess. 10 (2006) 1-83
28. Knapp M., Thorgrimsen L., Patel A., Spector A., Hallam A., Woods B., and Orrell M. Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis. Br. J. Psychiatry 188 (2006) 574-580
29. Manca A., Hawkins N., and Sculpher M.J. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 14 (2005) 487-496
30. Mangalore R., and Knapp M. Cost of schizophrenia in England. J. Ment. Health Policy Econ. 10 (2007) 22-41
31. McCrone P., Knapp M., Proudfoot J., Ryden C., Cavanagh K., Shapiro D.A., Ilson S., Gray J.A., Goldberg D., Mann A., Marks I., Everitt B., and Tylee A. Cost-effectiveness of computerised cognitive behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br. J. Psychiatry 185 (2004) 55-62
32. Myhr G., and Payne K. Cost-effectiveness of cognitive-behavioural therapy for mental disorders: implications for public health care funding policy in Canada. Can. J. Psychiatry 51 (2006) 662-670
33. Nice. Guide to the methods of technology appraisal. National Institute of Health and Clinical Excellence (NICE) publications (2008)
34. Palmer S., and Smith P.C. Incorporating option values into the economic evaluation of health care technologies. J. Health Econ. 19 (2000) 755-766
35. Priebe S., Jones G., Mccabe R., Briscoe J., Wright D., Sleed M., and Beecham J. Effectiveness and costs of acute day hospital treatment compared with conventional in-patient care. Br. J. Psychiatry 188 (2006) 243-249
36. Raftery J.P. Review of NICE's recommendations, 1999-2005. BMJ 332 (2006) 1266-1268
37. Roth P.L., Switzer F.S., and Switzer D. Missing data in multiple item scales: a Monte Carlo analysis of missing data techniques. Organ. Res. Methods 2 (1999) 211-232
38. Sach T.H., Barton G.R., Doherty M., Muir K., Jenkinson C., and Avery A.J. The relationship between BMI and health related quality of life: comparing the EQ-5D, EuroQol VAS, and SF-6D. Int. J. Obes. Relat. Metab. Disord. 31 (2007) 189-196
39. Torrance G.W., Raynauld J.P., Walker V., Goldsmith C.H., Bellamy N., Band P.A., Schultz M., Tugwell P., and Group C.K.O.A.S. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis: economic results. Osteoarthr. Cartil. 10 (2002) 518-527
40. van Roijen L.H., van Straten A., Al M., Rutten F., and Donker M. Cost-utility of brief psychological treatment for depression and anxiety. Br. J. Psychiatry 188 (2006) 323-329